Trophoblastic disease is associated with an increase in intact (whole-molecule) choriogonadotropin (hCG) and free /3-hCG subunits.' The mean ratio of free 13-hCG to hCG is highest in choriocarcinoma (mean = 18.6) and lowest in hydatidiform mole (mean = 8.8). The ratio in choriocarcinoma has been reported to be as high as 91 (1); a high ratio is predictive of high-risk disease, requiring multi-agent chemotherapy (2). Therefore, detection or monitoring of trophoblastic disease requires the use of a free /3-hCG subunit assay (1) or at least an assay that measures both the free /3-subunit and intact hCG. The same also applies to the detection of testicular and some gastrointestinal tumors, which may secrete only free /3-hCG subunits (3, 4). Tumors elaborating free a-chains ofhCG have also been reported (5). Some widely accepted immunochemical hCG assays measure only the intact molecule and not the free 3-subunit. These assays, when used alone, are not suitable for detecting or monitoring trophoblastic disease and some other types of tumors.
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We report here the 13-hCG and intact hCG results obtaiuied for a patient with choriocarcinoma and multiple metastases to the brain and lungs. Detailed information on the clinical course and treatment ofthe patient are reported elsewhere (6). Highlights are summarized in Table 1 .
Materials and Methods
The f3-hCG assay was carried out with the Tandem-R hCG test kit (Hybritech, Inc., San Diego, CA 92121), which detects both free 13-hCG subunits and intact hCG. The intact hCG assay was performed with a fluorometric enzyine immunoassay (Stratus hCG; American Dade, Miami, FL 33152), which detects only the intact hCG molecule. Both procedures are standardized against the World Health Organization's 1st International Reference Preparation UHF no. 75/537). Table 1 ). However, three months later, a modest increase in /3-hCG signaled possible recurrence of a tumor. Additional chemotherapy and a hysterectomy did not suppress the 13-hCG.
After five more months, a metastasis in the right lung, For the detection and monitoring of trophoblastic disease, this case clearly demonstrates the need for using a method that measures free 13-hCGsubunits. It also emphasizes the need to select assays that allow accurate measurement of f3-hCG values that only slightly exceed the normal reference interval.
